Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 10, 22 | -0.48
Increased by
+40.74%
|
-0.50
Increased by
+4.00%
|
Aug 11, 22 | -0.42
Increased by
+30.00%
|
-0.47
Increased by
+10.64%
|
May 12, 22 | -0.44
Decreased by
-15.79%
|
-0.58
Increased by
+24.14%
|
Mar 15, 22 | -0.57
Decreased by
-235.29%
|
-0.65
Increased by
+12.31%
|
Nov 9, 21 | -0.81
Decreased by
-50.00%
|
-0.39
Decreased by
-107.69%
|
Aug 10, 21 | -0.60
Increased by
+36.17%
|
-0.50
Decreased by
-20.00%
|
May 17, 21 | -0.38
Decreased by
-46.15%
|
-0.47
Increased by
+19.15%
|
Feb 25, 21 | -0.17
Increased by
+32.00%
|
-0.75
Increased by
+77.33%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 2.00 K
Decreased by
-98.73%
|
-23.52 M
Increased by
+29.83%
|
Decreased by
-1.18 M%
Decreased by
-5.43 K%
|
Jun 30, 22 | 8.00 K
Decreased by
-94.19%
|
-20.11 M
Increased by
+19.01%
|
Decreased by
-251.34 K%
Decreased by
-1.29 K%
|
Mar 31, 22 | 32.00 K
Decreased by
-96.18%
|
-19.43 M
Decreased by
-30.72%
|
Decreased by
-60.72 K%
Decreased by
-3.32 K%
|
Dec 31, 21 | -1.13 M
Decreased by
-148.79%
|
73.10 M
Increased by
+788.25%
|
Decreased by
-6.48 K%
Decreased by
-1.31 K%
|
Sep 30, 21 | 157.56 K
Decreased by
-94.64%
|
-33.51 M
Decreased by
-88.58%
|
Decreased by
-21.27 K%
Decreased by
-3.42 K%
|
Jun 30, 21 | 137.62 K
Decreased by
-80.93%
|
-24.83 M
Decreased by
-48.07%
|
Decreased by
-18.04 K%
Decreased by
-676.41%
|
Mar 31, 21 | 837.52 K
Decreased by
-62.15%
|
-14.86 M
Decreased by
-282.54%
|
Decreased by
-1.77 K%
Decreased by
-910.66%
|
Dec 31, 20 | 2.31 M
Increased by
+301.65%
|
-10.62 M
Decreased by
-159.28%
|
Decreased by
-459.28%
Increased by
+35.45%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.